Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $61.86 USD
Change Today 0.00 / 0.00%
Volume 0.0
AZNCF On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
Berlin
As of 8:10 PM 08/26/15 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc (AZNCF) Snapshot

Open
$61.86
Previous Close
$61.86
Day High
$61.86
Day Low
$61.86
52 Week High
09/19/14 - $75.20
52 Week Low
08/24/15 - $61.65
Market Cap
78.2B
Average Volume 10 Days
207.3
EPS TTM
--
Shares Outstanding
1.3B
EX-Date
08/13/15
P/E TM
--
Dividend
$3.11
Dividend Yield
4.98%
Current Stock Chart for ASTRAZENECA PLC (AZNCF)

astrazeneca plc (AZNCF) Details

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders; Pulmicort Turbuhaler/Pulmicort Flexhaler for treating asthma; Symbicort for maintenance treatment of asthma and chronic obstructive pulmonary disease; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. As of December 31, 2014, it had 133 pipeline projects. The company markets its products through distributors and local representative offices. It also engages in the insurance and reinsurance underwriting business. The company has collaboration agreements with Celgene Corporation, Immunocore Limited, Kyowa Hakko Kirin Co., Ltd., Advaxis Inc., Pharmacyclics Inc., and Janssen Research & Development, LLC., as well as a strategic collaboration with Isis Pharmaceuticals, Inc. to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. It also has a license from Heptares Therapeutics Ltd. to develop, manufacture, and commercialize the adenosine A2A receptor antagonist, HTL-1071. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

57,500 Employees
Last Reported Date: 03/10/15
Founded in 1992

astrazeneca plc (AZNCF) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.1M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 1.7M GBP
Compensation as of Fiscal Year 2014.

astrazeneca plc (AZNCF) Key Developments

Valeant Pharmaceuticals International, Inc. and Astrazeneca Enter Collaboration Agreement on Brodalumab

Valeant Pharmaceuticals International Inc. announced that its affiliate has entered into a collaboration agreement with AstraZeneca (AZN) under which Valeant was granted an exclusive license to develop and commercialize brodalumab. Brodalumab is an IL-17 receptor monoclonal antibody in development for patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. Under the agreement, Valeant will hold the exclusive rights to develop and commercialize brodalumab globally, except in Japan and certain other Asian countries where rights are held by Kyowa Hakko Kirin Co. Ltd. under a prior arrangement with Amgen Inc. Valeant will assume all development costs associated with the regulatory approval for brodalumab. Regulatory submission in US and EU for brodalumab in moderate-to-severe psoriasis is planned for the fourth quarter of 2015. As per agreement terms, Valeant will make an up-front payment to AstraZeneca of $100 million, as well as additional pre-launch milestones of up to $170 million and further sales-related milestone payments of up to $175 million following launch. After approval, AstraZeneca and Valeant will share profits. The company said it expects the transaction to complete in the fourth quarter of 2015, subject to customary closing conditions, including Hart-Scott-Rodino anti-trust clearance.

AstraZeneca PLC Signs License Agreement with Valeant Pharmaceuticals International, Inc

AstraZeneca PLC has entered into a collaboration agreement with Valeant Pharmaceuticals International Inc. under which AstraZeneca will grant an exclusive license for Valeant to develop and commercialize Brodalumab. Brodalumab is an IL-17 receptor monoclonal antibody in development for patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. Under the agreement, Valeant will hold the exclusive rights to develop and commercialize Brodalumab globally, except in Japan and certain other Asian countries where rights are held by Kyowa Hakko Kirin Co. Ltd. under a prior arrangement with Amgen Inc., the originator of Brodalumab. Under the terms of the agreement, Valeant will make an up-front payment to AstraZeneca of $100 million as well as additional pre-launch milestones of up to $170 million and further sales related milestone payments of up to $175 million following launch. After approval, AstraZeneca and Valeant will share profits. The transaction is expected to complete in the fourth quarter of 2015.

AstraZeneca and Peregrine Pharmaceuticals to Collaborate on Solid Tumor Trial

AstraZeneca and Peregrine Pharmaceuticals are collaborating on an early-phase clinical trial to evaluate the safety and efficacy of two novel investigational drugs in patients with a range of solid tumor types. The Phase 1/1b trial, slated to start in 2016, will combine it's durvalumab, an anti-PDL1 immune checkpoint inhibitor, with Peregrine's bavituximab, a phosphatidylserine-signaling pathway inhibitor. Preclinical data show that tumor-specific T-cells have a prolonged ability to continue attacking a tumor when the antitumor activity of bavituximab is combined with checkpoint inhibitors such as PDL1 antibodies, the companies say. The nonexclusive collaboration is the latest indication of significant interest in Peregrine's bavituximab as a potential key component in immuno-oncology combos, says company spokesman Tim Brons.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZNCF:US $61.86 USD 0.00

AZNCF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $139.69 USD +1.19
Abbott Laboratories $43.88 USD +0.31
Biogen Inc $300.20 USD +7.70
Eli Lilly & Co $80.85 USD +1.05
Valeant Pharmaceuticals International Inc C$301.10 CAD +4.90
View Industry Companies
 

Industry Analysis

AZNCF

Industry Average

Valuation AZNCF Industry Range
Price/Earnings 67.8x
Price/Sales 3.2x
Price/Book 4.4x
Price/Cash Flow 67.7x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.